PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 71 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2023. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,421,422 | -24.5% | 1,681,149 | +1.4% | 0.37% | -23.5% |
Q2 2023 | $5,853,428 | -2.3% | 1,658,195 | -14.4% | 0.49% | +17.0% |
Q1 2023 | $5,988,692 | -6.1% | 1,938,088 | +28.5% | 0.42% | -25.1% |
Q4 2022 | $6,377,414 | +78.7% | 1,507,663 | +0.1% | 0.56% | +80.6% |
Q3 2022 | $3,568,521 | -12.7% | 1,505,705 | +4.9% | 0.31% | +6.2% |
Q2 2022 | $4,089,969 | -0.3% | 1,435,077 | +0.7% | 0.29% | -7.6% |
Q1 2022 | $4,102,992 | +20.7% | 1,424,650 | +27.4% | 0.32% | +45.2% |
Q4 2021 | $3,398,410 | +21.8% | 1,117,898 | +180.9% | 0.22% | +11.9% |
Q3 2021 | $2,789,559 | +467.4% | 397,940 | +583.1% | 0.19% | +59.0% |
Q1 2020 | $491,638 | -42.9% | 58,251 | +37.7% | 0.12% | -73.8% |
Q4 2018 | $860,825 | -13.4% | 42,301 | +95.2% | 0.47% | +6.9% |
Q3 2018 | $993,615 | -29.8% | 21,671 | -9.4% | 0.44% | -32.6% |
Q2 2018 | $1,415,105 | -9.3% | 23,924 | +4.4% | 0.65% | -10.8% |
Q1 2018 | $1,559,978 | -71.1% | 22,924 | -58.1% | 0.72% | -76.7% |
Q4 2017 | $5,402,054 | – | 54,649 | – | 3.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |